Anti-SYUA/ SNCA/ NACP monoclonal antibody

Anti-SYUA/ SNCA/ NACP antibody for FACS & in-vivo assay

Target products collectionGo to SNCA/SNCA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T03644-Ab-1/ GM-Tg-hg-T03644-Ab-2Anti-Human SNCA monoclonal antibodyHuman
GM-Tg-rg-T03644-Ab-1/ GM-Tg-rg-T03644-Ab-2Anti-Rat SNCA monoclonal antibodyRat
GM-Tg-mg-T03644-Ab-1/ GM-Tg-mg-T03644-Ab-2Anti-Mouse SNCA monoclonal antibodyMouse
GM-Tg-cynog-T03644-Ab-1/ GM-Tg-cynog-T03644-Ab-2Anti-Cynomolgus/ Rhesus macaque SNCA monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T03644-Ab-1/ GM-Tg-felg-T03644-Ab-2Anti-Feline SNCA monoclonal antibodyFeline
GM-Tg-cang-T03644-Ab-1/ GM-Tg-cang-T03644-Ab-2Anti-Canine SNCA monoclonal antibodyCanine
GM-Tg-bovg-T03644-Ab-1/ GM-Tg-bovg-T03644-Ab-2Anti-Bovine SNCA monoclonal antibodyBovine
GM-Tg-equg-T03644-Ab-1/ GM-Tg-equg-T03644-Ab-2Anti-Equine SNCA monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T03644-Ab-1/ GM-Tg-hg-T03644-Ab-2; GM-Tg-rg-T03644-Ab-1/ GM-Tg-rg-T03644-Ab-2;
GM-Tg-mg-T03644-Ab-1/ GM-Tg-mg-T03644-Ab-2; GM-Tg-cynog-T03644-Ab-1/ GM-Tg-cynog-T03644-Ab-2;
GM-Tg-felg-T03644-Ab-1/ GM-Tg-felg-T03644-Ab-2; GM-Tg-cang-T03644-Ab-1/ GM-Tg-cang-T03644-Ab-2;
GM-Tg-bovg-T03644-Ab-1/ GM-Tg-bovg-T03644-Ab-2; GM-Tg-equg-T03644-Ab-1/ GM-Tg-equg-T03644-Ab-2
Products NameAnti-SNCA monoclonal antibody
Formatmab
Target NameSNCA
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Diagnostic target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SNCA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-106Pre-Made Cinpanemab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody
    BiosimilarGMP-Bios-ab-455Pre-Made Prasinezumab biosimilar, Whole mAb, Anti-SNCA Antibody: Anti-NACP/PARK1/PARK4/PD1 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species SYUA/ SNCA/ NACP VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMAAV000133human SNCA AAV particle
    ORF Viral VectorpGMLV000666human snca Lentivirus plasmid
    ORF Viral VectorvGMAD000007human SNCA Adenovirus particle
    ORF Viral VectorvGMLV000666human snca Lentivirus particle
    ORF Viral VectorpGMAAV000133human SNCA AAV plasmid
    ORF Viral VectorvGMLV000451human SNCA Lentivirus particle
    ORF Viral VectorpGMAD000007human SNCA Adenovirus plasmid
    ORF Viral VectorvGMAP000427Human SNCA Adenovirus particle
    ORF Viral VectorpGMAP000427Human SNCA Adenovirus plasmid
    ORF Viral VectorpGMLV000451human SNCA Lentivirus plasmid
    ORF Viral VectorpGMAAV000163mouse Snca AAV plasmid
    ORF Viral VectorvGMAAV000163mouse Snca AAV particle


    Target information

    Target IDGM-T03644
    Target NameSNCA
    Gene ID6622,20617,29219,706985,478478,101091694,282857,100053270
    Gene Symbol and Synonymsalpha-Syn,alphaSYN,NACP,PARK1,PARK4,PD1,SNCA
    Uniprot AccessionP37840,P37377,P61143,Q3T0G8
    Uniprot Entry NameSYUA_HUMAN,SYUA_MACMU,SYUA_RAT,SYUA_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Diagnostics Biomarker, INN Index
    DiseaseN/A
    Gene EnsemblENSG00000145335
    Target ClassificationN/A

    The target: SNCA, gene name: SNCA, also named as NACP, PARK1, PARK4, PD1. Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Alternatively spliced transcripts encoding different isoforms have been identified for this gene. [provided by RefSeq, Feb 2016].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.